-

Knowde Group Announces Successful Site Support Post Health Canada Non-Compliance Inspection

TORONTO--(BUSINESS WIRE)--Knowde Group (“Knowde”) provides clinical trial management services and strategic advisory focused on the conduct of phase I-III trials globally, including investigator initiated and registry trials. We are excited to announce the successful completion of our regulatory and site support post Health Canada inspection for Remedy Institute, which is a research site conducting phase 2 MDMA clinical trials in Canada. Health Canada deemed the Corrective and Preventative actions post Health Canada Inspection acceptable to resume conducting clinical trials.

As a result of the Health Canada Inspection and findings, The Remedy Institute did undergo a complete revision of their Quality Management Systems and staff training to address Health Canada’s GCP Inspection findings. Although inspections can be challenging to experience, it provides an opportunity for sites to improve compliance and study conduct,” said Jaspreet Grewal, CEO of Knowde Group.

The Knowde Group team manages psychedelic clinical trials, including site selection and feasibility, to help ensure the success of psychedelic clinical trials. There is currently a challenge finding sites globally to conduct clinical trials using psychedelic-assisted psychotherapy, and we support sponsors with site assessment and feasibility as this is one of the most critical decisions impacting a sponsor’s clinical trial program. This includes but is not limited to an experienced research site, risk mitigation plan, qualified and experienced study team, track record of recruiting participants, with the appropriate set and setting for extended safety monitoring, and insured and regulated investigator(s) trained in the use of psychedelics and with the therapeutic indication.

The proper conduct of clinical trials and ensuring participant safety are paramount to the success of any clinical program. As the psychedelic industry continues to grow, we are pleased to continue to provide our clients with the tools they need to find success in their research endeavours.

Knowde Group thanks Remedy Institute for choosing our team on this project and we congratulate the study team as they commence the conduct of their psychedelic clinical trials. Consider donating to Remedy Institute to support the important work that they are doing, information on how to donate can be found on their website www.remedyinstitute.ca.

About Knowde Group

Knowde Group, Inc is a female-minority founded company providing phase I to III clinical trial management services globally with offices in Canada, the US and the United Kingdom. In addition, Knowde Group provides consulting services to support Biotech and Life Sciences companies with strategic support from preclinical advisory up to commercialization, including reimbursement strategies. Knowde Group understands the importance of funding to drive clinical trials and innovation; as such Knowde Group provides a unique offering of connecting investors to viable biotech and life science companies that have a strong go-to-market strategy.

Contacts

For further information, please contact Sabrina Ramkellawan, Knowde Group at info@knowdegroup.com

Knowde Group, Inc


Release Versions

Contacts

For further information, please contact Sabrina Ramkellawan, Knowde Group at info@knowdegroup.com

More News From Knowde Group, Inc

BioAlberta Presents Achievement Awards at Annual Health and Life Sciences Showcase

EDMONTON, Alberta--(BUSINESS WIRE)--BioAlberta is proud to announce the recipients of the 2025 Achievement Awards at the Health and Life Sciences Showcase and Awards Dinner at the Hotel MacDonald in Edmonton on September 25th, 2025. This year’s Achievement Award recipients exemplify the outstanding contributions and innovations that they have brought to Alberta’s life sciences ecosystem. During Global Biotech Week and Life Sciences week, it is essential to honour the success of the past year of...

BioAlberta State of the Industry Report 2025 Highlights Strong Continued Growth in Alberta Life Sciences Sector

EDMONTON, Alberta--(BUSINESS WIRE)--Today BioAlberta released the State of the Industry report, 2025, which outlines the economic impact of Alberta’s vibrant life sciences sector and demonstrates the continued steady growth of life sciences and health innovation in Alberta. “The 2025 State of the Industry report is an important yardstick for life sciences and health innovation companies in Alberta. Despite a challenging investment climate, our sector continues to grow year-over-year. Life scien...

BioAlberta and AxialBridge Team Up to Support Alberta Life Sciences Companies Into the United Kingdom

CALGARY, Alberta--(BUSINESS WIRE)--BioAlberta is pleased to announce that it is partnering with AxialBridge as its operational and commercialization partner, to support Alberta biotechnology and MedTech companies looking to expand clinical and R&D opportunities into the United Kingdom. “With today’s announcement that BioAlberta will host a virtual office for the National Institute for Health and Care Research, we want to provide a service that supports companies to understand the UK market...
Back to Newsroom